BioCryst Pharmaceuticals Inc Financial Flexibility Index
BioCryst Pharmaceuticals Inc financial flexibility index. BioCryst Pharmaceuticals Inc (BCRX) has a Financial Flexibility Index of -0.06x as of March 2026. Free cash flow of $-61.73 Million (operating CF $-62.14 Million minus capex $403.00K) represents 0% of total liabilities ($1.02 Billion). Explore BioCryst Pharmaceuticals Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of BioCryst Pharmaceuticals Inc (1994–2025)
Financial flexibility index of BioCryst Pharmaceuticals Inc from 1994 to 2025. Historical Financial Flexibility Index trend for BioCryst Pharmaceuticals Inc across 32 annual periods. Check BioCryst Pharmaceuticals Inc (BCRX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BioCryst Pharmaceuticals Inc Financial Flexibility Index by Year (1994–2025)
BioCryst Pharmaceuticals Inc financial flexibility index by year from 1994 to 2025. Year-by-year free cash flow to debt coverage for BioCryst Pharmaceuticals Inc. For the full cash flow conversion analysis, see how efficiently does BioCryst Pharmaceuticals Inc generate cash.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.52x | $332.35 Million | $329.88 Million | $633.31 Million | ▲ +1096.4% |
| 2024 | -0.05x | $-50.90 Million | $-52.02 Million | $966.35 Million | ▲ +44.9% |
| 2023 | -0.10x | $-92.97 Million | $-95.14 Million | $972.49 Million | ▲ +49.7% |
| 2022 | -0.19x | $-160.50 Million | $-161.85 Million | $844.60 Million | ▲ +5.5% |
| 2021 | -0.20x | $-139.77 Million | $-142.16 Million | $695.14 Million | ▲ +47.9% |
| 2020 | -0.39x | $-136.70 Million | $-137.22 Million | $353.98 Million | ▲ +40.7% |
| 2019 | -0.65x | $-89.24 Million | $-89.58 Million | $137.03 Million | ▲ +31.1% |
| 2018 | -0.94x | $-92.20 Million | $-92.56 Million | $97.61 Million | ▼ -118.7% |
| 2017 | -0.43x | $-40.81 Million | $-41.14 Million | $94.49 Million | ▲ +20.8% |
| 2016 | -0.55x | $-48.16 Million | $-53.44 Million | $88.27 Million | ▼ -424.4% |
| 2015 | -0.10x | $-7.99 Million | $-13.12 Million | $76.83 Million | ▲ +83.4% |
| 2014 | -0.63x | $-38.45 Million | $-38.55 Million | $61.24 Million | ▼ -18.4% |
| 2013 | -0.53x | $-26.50 Million | $-26.53 Million | $49.99 Million | ▲ +17.7% |
| 2012 | -0.64x | $-37.28 Million | $-37.40 Million | $57.89 Million | ▼ -34.8% |
| 2011 | -0.48x | $-32.20 Million | $-32.25 Million | $67.40 Million | ▲ +25.6% |
| 2010 | -0.64x | $-28.23 Million | $-28.55 Million | $43.94 Million | ▼ -130.1% |
| 2009 | -0.28x | $-15.61 Million | $-16.22 Million | $55.92 Million | ▲ +45.7% |
| 2008 | -0.51x | $-19.66 Million | $-20.87 Million | $38.27 Million | ▼ -101.2% |
| 2007 | 42.65x | $3.32 Billion | $-25.00 Million | $77.81 Million | ▲ +14860.5% |
| 2006 | -0.29x | $-13.68 Million | $-15.21 Million | $47.33 Million | ▲ +48.4% |
| 2005 | -0.56x | $-22.85 Million | $-23.35 Million | $40.81 Million | ▲ +90.2% |
| 2004 | -5.70x | $-17.88 Million | $-18.15 Million | $3.13 Million | ▲ +15.6% |
| 2003 | -6.76x | $-11.14 Million | $-11.20 Million | $1.65 Million | ▲ +50.3% |
| 2002 | -13.61x | $-15.96 Million | $-16.36 Million | $1.17 Million | ▼ -311.2% |
| 2001 | -3.31x | $-7.55 Million | $-10.16 Million | $2.28 Million | ▼ -6707.2% |
| 2000 | -0.05x | $-454.34K | $-3.18 Million | $9.35 Million | ▲ +97.5% |
| 1999 | -1.95x | $-3.90 Million | $-4.90 Million | $2.00 Million | ▲ +28.2% |
| 1998 | -2.71x | $-3.80 Million | $-4.20 Million | $1.40 Million | ▲ +64.6% |
| 1997 | -7.67x | $-9.20 Million | $-10.30 Million | $1.20 Million | ▼ -100.5% |
| 1996 | -3.82x | $-6.50 Million | $-6.80 Million | $1.70 Million | ▲ +8.2% |
| 1995 | -4.17x | $-7.50 Million | $-7.70 Million | $1.80 Million | ▼ -9.3% |
| 1994 | -3.81x | $-6.10 Million | $-6.50 Million | $1.60 Million | — |